Page 117 - Read Online

Page 12 of 12 Schofield et al. J Cancer Metastasis Treat 2020;6:10 I http://dx.doi.org/10.20517/2394-4722.2019.43

69. Su S, Xu H, Chen X, Qiao G, Farooqi AA, et al. CS5931, A novel marine polypeptide, inhibits migration and invasion of cancer cells via
interacting with enolase 1. Recent Pat Anticancer Drug Discov 2018;13:360-7.
70. Yu L, Shi J, Cheng S, Zhu Y, Zhao X, et al. Estrogen promotes prostate cancer cell migration via paracrine release of ENO1 from stromal
cells. Mol Endocrinol 2012;26:1521-30.
71. Principe M, Ceruti P, Shih NY, Chattaragada MS, Rolla S, et al. Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic
cancer cells. Oncotarget 2015;6:11098-113.
72. Hsiao KC, Shih NY, Fang HL, Huang TS, Kuo CC, et al. Surface alpha-enolase promotes extracellular matrix degradation and tumor
metastasis and represents a new therapeutic target. PLoS One 2013;8:e69354.
73. Chang GC, Liu KJ, Hsieh CL, Hu TS, Charoenfuprasert S, et al. Identification of alpha-enolase as an autoantigen in lung cancer: its
overexpression is associated with clinical outcomes. Clin Cancer Res 2006;12:5746-54.
74. Dai L, Qu Y, Li J, Wang X, Wang K, et al. Serological proteome analysis approach-based identification of ENO1 as a tumor-associated
antigen and its autoantibody could enhance the sensitivity of CEA and CYFRA 21-1 in the detection of non-small cell lung cancer.
Oncotarget 2017;8:36664-73.
75. Qin J, Wang S, Shi J, Ma Y, Wang K, et al. Using recursive partitioning approach to select tumor-associated antigens in immunodiagnosis
of gastric adenocarcinoma. Cancer Sci 2019;110:1829-41.
76. Suzuki A, Iizuka A, Komiyama M, Takikawa M, Kume A, et al. Identification of melanoma antigens using a Serological Proteome
Approach (SERPA). Cancer Genomics Proteomics 2010;7:17-23.
77. Cui JW, Li WH, Wang J, Li AL, Li HY, et al. Proteomics-based identification of human acute leukemia antigens that induce humoral
immune response. Mol Cell Proteomics 2005;4:1718-24.
78. Zou L, Wu Y, Pei L, Zhong D, Gen M, et al. Identification of leukemia-associated antigens in chronic myeloid leukemia by proteomic
analysis. Leuk Res 2005;29:1387-91.
79. Forgber M, Trefzer U, Sterry W, Walden P. Proteome serological determination of tumor-associated antigens in melanoma. PLoS One
2009;4:e5199.
80. Kondo H, Sahara H, Miyazaki A, Nabeta Y, Hirohashi Y, et al. Natural antigenic peptides from squamous cell carcinoma recognized by
autologous HLA-DR8-restricted CD4+ T cells. Jpn J Cancer Res 2002;93:917-24.
81. Cappello P, Rolla S, Chiarle R, Principe M, Cavallo F, et al. Vaccination with ENO1 DNA prolongs survival of genetically engineered
mice with pancreatic cancer. Gastroenterology 2013;144:1098-106.
82. Yang M, Sun Y, Sun J, Wang Z, Zhou Y, et al. Differentially expressed and survival-related proteins of lung adenocarcinoma with bone
metastasis. Cancer Med 2018;7:1081-92.
83. Zhou H, Chen CB, Lan J, Liu C, Liu XG, et al. Differential proteomic profiling of chordomas and analysis of prognostic factors. J Surg
Oncol 2010;102:720-7.
84. White-Al Habeeb NM, Di Meo A, Scorilas A, Rotondo F, Masui O, et al. Alpha-enolase is a potential prognostic marker in clear cell renal
cell carcinoma. Clin Exp Metastasis 2015;32:531-41.
85. Hsiao KC, Shih NY, Chu PY, Hung YM, Liao JY, et al. Anti-alpha-enolase is a prognostic marker in postoperative lung cancer patients.
Oncotarget 2015;6:35073-86.
86. Tomaino B, Cappello P, Capello M, Fredolini C, Sperduti I, et al. Circulating autoantibodies to phosphorylated alpha-enolase are a
hallmark of pancreatic cancer. J Proteome Res 2011;10:105-12.
87. Niccolai E, Cappello P, Taddei A, Ricci F, D’Elios MM, et al. Peripheral ENO1-specific T cells mirror the intratumoral immune response
and their presence is a potential prognostic factor for pancreatic adenocarcinoma. Int J Oncol 2016;49:393-401.
88. Shih NY, Lai HL, Chang GC, Lin HC, Wu YC, et al. Anti-alpha-enolase autoantibodies are down-regulated in advanced cancer patients.
Jpn J Clin Oncol 2010;40:663-9.
89. Zhang L, Wang H, Dong X. Diagnostic value of alpha-enolase expression and serum alpha-enolase autoantibody levels in lung cancer. J
Bras Pneumol 2018;44:18-23.
90. Griggio V, Mandili G, Vitale C, Capello M, Macor P, et al. Humoral immune responses toward tumor-derived antigens in previously
untreated patients with chronic lymphocytic leukemia. Oncotarget 2017;8:3274-88.
91. Yu YQ, Wang L, Jin Y, Zhou JL, Geng YH, et al. Identification of serologic biomarkers for predicting microvascular invasion in
hepatocellular carcinoma. Oncotarget 2016;7:16362-71.
92. Fortunato S, Bononi G, Granchi C, Minutolo F. An update on patents covering agents that interfere with the cancer glycolytic cascade.
ChemMedChem 2018;13:2251-65.